NEO Stock Chart & Stats
$176.40
$0.00(0.00%)
At close: 4:00 PM EDT
$176.40
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$176.40 - $217.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$29.84B
Enterprise Value$1.22K
Total Cash (Recent Filing)$145.54M
Total Debt (Recent Filing)$448.37M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Nov 10, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding130,211,780
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.36
Price to Sales (P/S)0.41
P/FCF Ratio-13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$296.53Price Target Upside68.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)3.14
Revenue Forecast (FY)$13.96B
Bulls Say, Bears Say
Bulls Say
NGS-driven Revenue Mix ShiftSustained 26% NGS growth and NGS representing ~1/3 of clinical revenue signals a structural mix shift toward higher-complexity, higher-AUP testing. This enhances gross-margin potential, strengthens clinical stickiness with oncologists and pharma partners, and supports durable revenue growth as precision oncology adoption expands.
Improving Cash GenerationOperating cash flow turning positive (TTM ~ $22M) and management expecting FCF positivity for the year indicate improving self-funding capacity. Durable cash generation reduces reliance on external financing, supports reinvestment in sales/NGS capacity, and materially de-risks execution versus earlier negative cash-flow periods.
Regulatory & Governance De-riskingFinalizing the DOJ/OIG settlement removes a legacy legal overhang and the below-reserve payment preserves capital. Coupled with adding a data-focused independent director, this materially lowers regulatory and governance uncertainty and strengthens strategic oversight for data/AI-driven diagnostics expansion.
Bears Say
Persistent Negative ProfitabilityDespite revenue growth, persistent negative operating and net margins (TTM ~-7% and -6.8%) and negative ROE constrain internal capital generation. Over the medium term this limits funding for R&D and sales expansion, increases dependence on external capital, and prolongs vulnerability to reimbursement or volume shocks.
Payer/Reimbursement UncertaintyNew product monetization (PanTracer LBx, RaDaR ST) depends on commercial payer coverage and Medicare timing. Delays or limited coverage would constrain realized AUPs and slow clinician adoption, making revenue and margin improvements contingent on external payor decisions rather than purely on commercial execution.
Capital Structure & Refinancing RiskA sizable convertible due 2028 necessitates refinancing and the company issued new 2032 notes while repurchasing 2028 paper. Reliance on private convertibles and capped calls creates execution and dilution risk; missteps or adverse markets could increase cost of capital or dilute equity, affecting long-term returns.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $176.40 and its highest was $217.50 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $29.84B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 10, 2026 which is in 104 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 28, 2026. The company reported $0.872 earnings per share for the quarter, beating the consensus estimate of $0.593 by $0.279.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.92.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 130,211,780 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.872 in its last earnings report, beating expectations of $0.593. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in MX:NEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$296.53 (68.10% Upside)
$296.53 (68.10% Upside)
Blogger Sentiment
Bullish
MX:NEO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $118.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.92%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
NEO Company Deck
NEO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive operational and financial trajectory: consistent double-digit top-line growth, strong NGS performance (+26% YoY) with favorable mix shift (NGS now ~1/3 of clinical revenue), adjusted EBITDA expansion (+27% YoY), early commercial and reimbursement wins (PanTracer MolDX approval, RaDaR ST launch), and an increase to full-year revenue guidance. Offsetting risks include a meaningful nonclinical decline (-15% YoY), first-quarter gross margin headwinds (–80 bps) from acquisition and pre-approval launch timing, freight/fuel cost pressure, payer coverage timing for new products, and the need to refinance a sizable convertible in 2028. On balance, the positive growth, margin recovery plans, product launches, and improved cash flow prospects outweigh the near-term headwinds.View all MX:NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$296.53
▲(68.10% Upside)